Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POTIGA is an oral small-molecule tablet approved by GSK in June 2011 for an undisclosed indication. The specific mechanism of action and therapeutic area remain unavailable in the provided data.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable but potentially maturing commercial operations and team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POTIGA currently shows zero linked job postings, indicating minimal active hiring or team expansion. Working on this peak-stage product offers exposure to mature market management and sales optimization, but limited growth trajectory opportunity.
Brand ManagerField Sales Representative
Worked on POTIGA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.